Pregnancy drugs, fetal germline epigenome, and risks for next‐generation pathology: A call to action

Abstract

Drugs taken during pregnancy can affect three generations at once: the gestating woman (F0), her exposed fetus (F1), and the fetal germ cells that confer heritable information for the grandchildren (F2). Unfortunately, despite growing evidence for connections between F0 drug exposures and F2 pathology, current approaches to risk assessment overlook this important dimension of risk. In this commentary, we argue that the unique molecular vulnerabilities of the fetal germline, particularly with regard to global epigenomic reprogramming, combined with empirical evidence for F2 effects of F1 in utero drug and other exposures, should change the way we consider potential long‐term consequences of pregnancy drugs and alter toxicology's standard somatic paradigm. Specifically, we (1) suggest that pregnancy drugs common in the postwar decades should be investigated as potential contributors to the “missing heritability” of many pathologies now surging in prevalence; (2) call for inclusion of fetal germline risks in pregnancy drug safety assessment; and (3) highlight the need for intensified research to ascertain generational impacts of diethylstilbestrol, a vanguard question of human germline toxicity. Only by fully addressing this important dimension of transplacental exposure can we responsibly evaluate safety of drug exposures during pregnancy and convey the full scope of risks, while also retrospectively comprehending the generational legacy of recent history's unprecedented glut of evolutionarily novel intrauterine exposures. Environ. Mol. Mutagen. 60:445–454, 2019. © 2019 Wiley Periodicals, Inc.

The epigenetic legacy of illicit drugs: developmental exposures and late-life phenotypes

“…Exposure of the developing fetus represents a perturbation of a key epigenetic critical period during which exogenous chemicals have the potential to adversely affect not only the F1 but also the F2 generation, which can be exposed during F1 PGC development. Not even FDA-approved pharmaceuticals are routinely tested for adverse germline effects, and illicit drugs taken at unknown doses and purities are of great concern for the eventual adult health of children and grand-children being exposed in utero [117]. Part of the solution to this problem will involve improving the clinical applicability of animal model exposures: cannabis, for example, is composed of hundreds of phytocannabinoid compounds and terpenes that are thought to modulate one another’s activity at different concentrations (i.e.…”

General anesthesia, germ cells and the missing heritability of autism: an urgent need for research

“…Interestingly, the new field of antenatal corrective surgery requires particularly high concentrations of sevoflurane to relax the uterus over many hours, exposing an undeveloped fetus to unprecedented quantities of GA [ 45 ]. That said, any pregnancy GA exposure generally will reach the embryo or fetus, exposing the developing germline, an important concern since early stage germ cells possess heightened vulnerabilities to toxicants [ 30 ].…”

“…Grandmaternal smoking in pregnancy was found to be associated with increased risk for autism traits and diagnosed autism in grandoffspring in the UK’s ALSPAC cohort [ 29 ]. And in what is perhaps the most convincing evidence that human germ cell exposures can result in offspring pathology generally, grandmaternal DES has been seen in human studies to increase risks for grandchild pathologies such as urogenital abnormalities and cancers [ 30 ].…”

Heritable hazards of smoking: Applying the “clean sheet” framework to further science and policy

“…Several large cohort studies already exist in multiple countries, and the available data could be readily leveraged for this purpose. Specifically, a human study investigating the F 2 health effects from F 0 grandmaternal smoking where the F 0 smoking dose is known would improve our understanding of heritable effects established during PGC development (Escher and Robotti 2019). Multiple phenotypic endpoints in the F 2 generation should be evaluated, including those related to cardiopulmonary, allergy/asthma, metabolic, and neurodevelopmental disorders and diseases.…”